PRESS RELEASE published on 11/12/2025 at 07:30, 4 months 12 days ago Informations privilégiées / Autres communiqués ADOCIA dépose un brevet pour une nouvelle plateforme de peptides à action prolongée, AdoXLongTM, et fait avancer sa technologie BioChaperone® pour le traitement du diabète et de l'obésité Obésité Diabète ADOCIA Peptides Action Prolongée
PRESS RELEASE published on 11/12/2025 at 07:30, 4 months 12 days ago Inside Information / Other news releases Adocia files patent for AdoXLongTM platform to extend duration of action for peptides in diabetes and obesity treatment. BioChaperone® platform updated with feasibility studies Obesity Treatment Diabetes Treatment Patent Filing ADOCIA AdoXLongTM
BRIEF published on 10/21/2025 at 10:47, 5 months 3 days ago Franchissement de seuils chez ADOCIA Actions Franchissement De Seuils Bons De Souscription ADOCIA Vester Finance
BRIEF published on 10/21/2025 at 10:47, 5 months 3 days ago Crossing thresholds at ADOCIA Warrants Actions Crossing Thresholds ADOCIA Vester Finance
PRESS RELEASE published on 10/21/2025 at 10:42, 5 months 3 days ago Franchissement de seuils Déclaration de franchissement de seuils par Vester Finance pour ADOCIA avec 889 555 actions, 4,86% du capital et 4,36% des droits de vote Déclaration Actions Franchissement De Seuils ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 5 months 9 days ago Résultats positifs pour l'insuline BioChaperone® Lispro en Phase 3 Essai Clinique Diabète De Type 1 ADOCIA BioChaperone® Tonghua Dongbao
BRIEF published on 10/15/2025 at 08:50, 5 months 9 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 5 months 9 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
PRESS RELEASE published on 10/15/2025 at 08:45, 5 months 9 days ago Informations privilégiées / Autres communiqués Adocia et Tonghua Dongbao annoncent des résultats positifs d'essai clinique de Phase 3 sur l'insuline BioChaperone® Lispro THDB0206 injection pour le Diabète de Type 1 en Chine Diabète De Type 1 ADOCIA Tonghua Dongbao Insuline BioChaperone Lispro
BRIEF published on 07/25/2025 at 08:50, 7 months 30 days ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
Published on 03/24/2026 at 13:30, 5 hours 25 minutes ago GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada
Published on 03/24/2026 at 13:30, 5 hours 25 minutes ago Innodata Announces Date of Annual Shareholder Meeting
Published on 03/24/2026 at 12:35, 6 hours 20 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 6 hours 22 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 12:30, 6 hours 25 minutes ago Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
Published on 03/24/2026 at 18:39, 15 minutes ago EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026
Published on 03/24/2026 at 18:00, 55 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 03/24/2026 at 17:50, 1 hour 5 minutes ago Annual General Meeting of Bellevue Group AG – all proposals approved
Published on 03/24/2026 at 16:50, 2 hours 5 minutes ago LR Health & Beauty SE announces successful conclusion of the Written Procedure initiated on 6 March 2026 under the 2024/2028 Bonds and issuance of Super Senior Bonds
